Ethical considerations in studying drug safety--the Institute of Medicine report.

In May 2012, the Institute of Medicine (IOM) issued a report on the ethics and science of FDA-required postmarketing safety research. Three members of the IOM committee discuss the committee's ethics findings.

[1]  R. Misbin.  Lessons From the Avandia Controversy , 2007, Diabetes Care.

[2]  M. Hamburg,et al.  Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. , 2010, The New England journal of medicine.

[3]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[4]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[5]  D. Solomon.  Selective cyclooxygenase 2 inhibitors and cardiovascular events. , 2005, Arthritis and rheumatism.

[6]  S. Nissen.  The rise and fall of rosiglitazone. , 2010, European heart journal.

[7]  Jeffrey M Drazen,et al.  Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. , 2005, The New England journal of medicine.

[8]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[9]  K. Aaronson,et al.  Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.

[10]  Tom Jefferson,et al.  The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience , 2012, PLoS medicine.

[11]  E. Topol,et al.  Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.

[12]  K. Aaronson,et al.  Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials , 2005 .

[13]  S. Yusuf,et al.  Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial , 2011, Diabetologia.

[14]  Aaron S Kesselheim,et al.  Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. , 2007, Health affairs.

[15]  A. Park,et al.  CENTER FOR DRUG EVALUATION AND RESEARCH , 2009 .

[16]  M. A. Carter,et al.  Bioethics and Post-approval Research in Translational Science , 2010, The American journal of bioethics : AJOB.

[17]  S. Nissen,et al.  Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. , 2010, Archives of internal medicine.

[18]  C. Levine.  Has AIDS Changed the Ethics of Human Subjects Research? , 1988, Law, medicine & health care : a publication of the American Society of Law & Medicine.

[19]  Lisa Bero,et al.  Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation , 2008, PLoS medicine.

[20]  B. Psaty,et al.  A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. , 2012, JAMA.

[21]  J. Kimmelman,et al.  Rethinking Research Ethics: The Case of Postmarketing Trials , 2012, Science.